Amycretin UK: The New Weight Loss Drug Explained
Amycretin is an investigational weight loss drug being developed by Novo Nordisk, the pharmaceutical company behind established treatments like Wegovy and Ozempic. It is a dual incretin receptor agonist, targeting both GLP-1 (glucagon-like peptide-1) and amylin receptors to help with significant weight reduction.Amycretin is currently in clinical trials and is not yet available for general use but has already shown promising results, with patients achieving up to 24% body weight loss in recent studies. Once approved, it is expected to be a strong competitor to Mounjaro (tirzepatide) and Wegovy (semaglutide).
How Does Amycretin Work?
Amycretin’s weight loss mechanism is based on dual hormone activation:
1. GLP-1 Receptor Agonist
- Slows gastric emptying
- Reduces appetite and food cravings
- Enhances insulin secretion and lowers blood glucose
2. Amylin Receptor Agonist
- Promotes satiety (feeling full)
- Reduces calorie intake
- Regulates glucose metabolism
This combined approach makes Amycretin potentially more effective than single-target GLP-1 therapies, leading to faster, more sustained weight loss.
Amycretin Clinical Trial Results
According to data released in June 2025 from Novo Nordisk’s Phase II trial:
- Participants on Amycretin lost an average of 24% of their body weight over 46 weeks.
- Comparable to or exceeding weight loss seen with tirzepatide (Mounjaro) and semaglutide (Wegovy).
- Amycretin was generally well tolerated, with common side effects including nausea, vomiting, and constipation.
Expected Use Cases for Amycretin
Amycretin is being explored for both obesity management and type 2 diabetes. Its potential applications include:
- Adults with BMI ≥30 kg/m² (obese)
- Adults with BMI ≥27 kg/m² with weight-related conditions (e.g., hypertension, PCOS)
- Possibly for prediabetes or insulin resistance in future studies
It is not yet authorised for use, but UK patients are showing high demand based on preliminary trial success.
Amycretin vs Mounjaro vs Wegovy
| Feature | Amycretin | Mounjaro (Tirzepatide) | Wegovy (Semaglutide) |
| Mechanism | GLP-1 + Amylin | GLP-1 + GIP | GLP-1 only |
| Avg Weight Loss | ~24% (trial data) | ~22.5% | ~15% |
| Injection Frequency | Weekly (expected) | Weekly | Weekly |
| Manufacturer | Novo Nordisk | Eli Lilly | Novo Nordisk |
Amycretin has gained attention for its unique GLP-1 targeting and promising weight loss outcomes. But how does it perform when stacked up against other leading options? If you’re curious about how Amycretin compares to Wegovy in terms of results, side effects, and cost, check out our detailed comparison here: Amycretin vs Wegovy Weight Loss Comparison.
Side Effects of Amycretin
Like other injectable weight loss medications, Amycretin may cause temporary side effects such as:
- Nausea or vomiting
- Diarrhoea or constipation
- Abdominal discomfort
- Fatigue or dizziness
These typically reduce as the body adjusts. Long-term safety data will become available after ongoing trials are completed.
When Will Amycretin Be Available in the UK?
Amycretin is currently in Phase 2 clinical trials, with Phase 3 trials expected to start in late 2025. If all goes well, the drug could be available for UK patients by 2026 or early 2027, subject to MHRA and EMA approval.
In the meantime, MedCare Health Clinic will monitor availability and offer Amycretin consultations once legally permitted.
Can You Pre-Register for Amycretin?
At MedCare Health Clinic, we offer a priority waitlist for patients interested in upcoming weight loss medications like Amycretin. This allows us to notify eligible patients as soon as:
- The product becomes licensed in the UK
- Clinical guidance is released
- Consultation pathways open for private prescription
Join the list by visiting our clinic or completing our online interest form.
Final Thoughts
Amycretin represents the next evolution in weight loss treatment, with dual-action power and game-changing trial outcomes. For patients struggling with obesity or related health conditions, it could offer a highly effective, once-weekly solution.
Stay informed by following MedCare Health Clinic for the latest updates on Amycretin, GLP-1 medications, and trusted weight loss services in the UK.